基质金属蛋白酶在肾脏稳态和疾病中的作用。
Matrix metalloproteinases in kidney homeostasis and diseases.
机构信息
Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, 200 Lothrop St., Pittsburgh, PA 15261, USA.
出版信息
Am J Physiol Renal Physiol. 2012 Jun 1;302(11):F1351-61. doi: 10.1152/ajprenal.00037.2012. Epub 2012 Apr 4.
Abstract
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that have been increasingly linked to both normal physiology and abnormal pathology in the kidney. Collectively able to degrade all components of the extracellular matrix, MMPs were originally thought to antagonize the development of fibrotic diseases solely through digestion of excessive matrix. However, increasing evidence has shown that MMPs play a wide variety of roles in regulating inflammation, epithelial-mesenchymal transition, cell proliferation, angiogenesis, and apoptosis. We now have robust evidence for MMP dysregulation in a multitude of renal diseases including acute kidney injury, diabetic nephropathy, glomerulonephritis, inherited kidney disease, and chronic allograft nephropathy. The goal of this review is to summarize current findings regarding the role of MMPs in kidney diseases as well as the mechanisms of action of this family of proteases.
摘要
基质金属蛋白酶（MMPs）是一类锌依赖性内肽酶，它们与肾脏的正常生理和异常病理均有越来越密切的联系。MMPs 能够降解细胞外基质的所有成分，最初被认为仅通过消化过多的基质来拮抗纤维性疾病的发展。然而，越来越多的证据表明，MMPs 在调节炎症、上皮-间充质转化、细胞增殖、血管生成和细胞凋亡等方面发挥着广泛的作用。目前已经有大量证据表明，MMPs 在多种肾脏疾病中失调，包括急性肾损伤、糖尿病肾病、肾小球肾炎、遗传性肾脏疾病和慢性移植肾肾病。本综述的目的是总结 MMPs 在肾脏疾病中的作用以及该蛋白酶家族的作用机制的最新发现。
相似文献
1
Matrix metalloproteinases in kidney homeostasis and diseases.基质金属蛋白酶在肾脏稳态和疾病中的作用。
Am J Physiol Renal Physiol. 2012 Jun 1;302(11):F1351-61. doi: 10.1152/ajprenal.00037.2012. Epub 2012 Apr 4.
2
Role of matrix metalloproteinases in renal pathophysiologies.基质金属蛋白酶在肾脏病理生理学中的作用。
Am J Physiol Renal Physiol. 2007 Mar;292(3):F905-11. doi: 10.1152/ajprenal.00421.2006. Epub 2006 Dec 26.
3
Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal.基质金属蛋白酶在肾脏疾病中的作用：批判性评价。
Kidney Blood Press Res. 2019;44(3):298-330. doi: 10.1159/000499876. Epub 2019 Jun 11.
4
Matrix metalloproteinases in kidney homeostasis and diseases: an update.基质金属蛋白酶在肾脏稳态和疾病中的作用：最新研究进展。
Am J Physiol Renal Physiol. 2024 Dec 1;327(6):F967-F984. doi: 10.1152/ajprenal.00179.2024. Epub 2024 Oct 3.
5
Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease.基质金属蛋白酶和基质金属蛋白酶组织抑制剂与肾脏疾病。
Adv Clin Chem. 2021;105:141-212. doi: 10.1016/bs.acc.2021.02.003. Epub 2021 Mar 9.
6
Kidney Fibrosis and Matrix Metalloproteinases (MMPs).肾纤维化与基质金属蛋白酶（MMPs）
Front Biosci (Landmark Ed). 2024 May 16;29(5):192. doi: 10.31083/j.fbl2905192.
7
A glimpse of matrix metalloproteinases in diabetic nephropathy.糖尿病肾病中基质金属蛋白酶的一瞥。
Curr Med Chem. 2014;21(28):3244-60. doi: 10.2174/0929867321666140716092052.
8
Matrix Metalloproteinases in Kidney Disease: Role in Pathogenesis and Potential as a Therapeutic Target.基质金属蛋白酶在肾脏疾病中的作用：在发病机制中的角色及作为治疗靶点的潜力
Prog Mol Biol Transl Sci. 2017;148:31-65. doi: 10.1016/bs.pmbts.2017.03.001. Epub 2017 May 4.
9
Matrix metalloproteinases in vascular physiology and disease.基质金属蛋白酶在血管生理与疾病中的作用
Vascular. 2012 Aug;20(4):210-6. doi: 10.1258/vasc.2011.201202. Epub 2012 Aug 15.
10
Role of Matrix Metalloproteinases in Degenerative Kidney Disorders.基质金属蛋白酶在退行性肾脏疾病中的作用。
Curr Med Chem. 2018;25(15):1805-1816. doi: 10.2174/0929867325666171205143441.
引用本文的文献
1
Kidney Transplant Recipients with Acute Antibody-Mediated Rejection Show Altered Levels of Matrix Metalloproteinases and Their Inhibitors: Evaluation of Circulating MMP and TIMP Profiles.急性抗体介导排斥反应的肾移植受者显示基质金属蛋白酶及其抑制剂水平改变：循环MMP和TIMP谱的评估。
Int J Mol Sci. 2025 Jun 23;26(13):6011. doi: 10.3390/ijms26136011.
2
Cardiovascular and Renal Outcomes Following Repeated Naringenin Exposure in Normotensive and Hypertensive Rats.正常血压和高血压大鼠反复接触柚皮素后的心血管和肾脏结局
Pharmaceuticals (Basel). 2025 Jun 12;18(6):873. doi: 10.3390/ph18060873.
3
Fibroblast activation and heterogeneity in fibrotic disease.纤维化疾病中的成纤维细胞激活与异质性。
Nat Rev Nephrol. 2025 Jun 19. doi: 10.1038/s41581-025-00969-8.
4
Metalloproteinases (MMPs) in hypertensive disorders: role, function, pharmacology, and potential strategies to mitigate pathophysiological changes.高血压疾病中的金属蛋白酶（MMPs）：作用、功能、药理学及减轻病理生理变化的潜在策略
Front Pharmacol. 2025 May 26;16:1559288. doi: 10.3389/fphar.2025.1559288. eCollection 2025.
5
Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide.布地奈德治疗的IgA肾病患者蛋白尿进展中尿生物标志物的预后价值
Medicina (Kaunas). 2025 Apr 26;61(5):807. doi: 10.3390/medicina61050807.
6
Transcriptomic Approach in Understanding Fabry Nephropathy: A Review of the Literature and Proof-of-Concept.转录组学方法在理解法布里肾病中的应用：文献综述与概念验证
Genes (Basel). 2025 May 19;16(5):601. doi: 10.3390/genes16050601.
7
Significant Changes in Low-Abundance Protein Content Detected by Proteomic Analysis of Urine from Patients with Renal Stones After Extracorporeal Shock Wave Lithotripsy.体外冲击波碎石术后肾结石患者尿液蛋白质组分析检测到低丰度蛋白质含量的显著变化。
Biology (Basel). 2025 Apr 27;14(5):482. doi: 10.3390/biology14050482.
8
Spatially resolved transcriptomic profiling for glomerular and tubulointerstitial gene expression in C3 glomerulopathy.C3肾小球病中肾小球和肾小管间质基因表达的空间分辨转录组分析
Clin Kidney J. 2025 May 8;18(5):sfaf139. doi: 10.1093/ckj/sfaf139. eCollection 2025 May.
9
Gel Zymography for the Evaluation of Matrix Metalloproteinase-2 and -9 in Aorta and Kidney Tissues.用于评估主动脉和肾脏组织中基质金属蛋白酶-2和-9的凝胶酶谱分析
Methods Mol Biol. 2025;2917:87-97. doi: 10.1007/978-1-0716-4478-2_8.
10
Post-ESWL urinary osteopontin level and ion-activity product of calcium oxalate are associated with stone recurrence after 5-year follow-up.体外冲击波碎石术后5年随访发现，尿骨桥蛋白水平和草酸钙离子活性产物与结石复发相关。
BMC Urol. 2025 Apr 24;25(1):102. doi: 10.1186/s12894-025-01791-x.
本文引用的文献
1
Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism.基质金属蛋白酶-10 通过一种凝血酶激活的纤维蛋白溶解抑制剂介导的机制有效减少实验性中风中的梗塞面积，增强纤维蛋白溶解。
Circulation. 2011 Dec 20;124(25):2909-19. doi: 10.1161/CIRCULATIONAHA.111.047100. Epub 2011 Nov 21.
2
Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/β-catenin activity in CKD.基质金属蛋白酶-7 作为替代标志物预测 CKD 中的肾脏 Wnt/β-连环蛋白活性。
J Am Soc Nephrol. 2012 Feb;23(2):294-304. doi: 10.1681/ASN.2011050490. Epub 2011 Nov 17.
3
An alternate perspective on the roles of TIMPs and MMPs in pathology.TIMPs 和 MMPs 在病理学中的作用的另一种观点。
Am J Pathol. 2012 Jan;180(1):12-6. doi: 10.1016/j.ajpath.2011.09.008. Epub 2011 Oct 25.
4
Cellular and molecular mechanisms of renal fibrosis.肾脏纤维化的细胞和分子机制。
Nat Rev Nephrol. 2011 Oct 18;7(12):684-96. doi: 10.1038/nrneph.2011.149.
5
Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis.基质金属蛋白酶 3 是肺纤维化的介质。
Am J Pathol. 2011 Oct;179(4):1733-45. doi: 10.1016/j.ajpath.2011.06.041. Epub 2011 Aug 24.
6
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria.经典 Wnt/β-连环蛋白信号通路介导转化生长因子-β1 诱导的足细胞损伤和蛋白尿。
Kidney Int. 2011 Dec;80(11):1159-1169. doi: 10.1038/ki.2011.255. Epub 2011 Aug 10.
7
Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis.靶向抑制β-catenin/CBP 信号转导可改善肾间质纤维化。
J Am Soc Nephrol. 2011 Sep;22(9):1642-53. doi: 10.1681/ASN.2010101079. Epub 2011 Aug 4.
8
Distinct metalloproteinase excretion patterns in focal segmental glomerulosclerosis.局灶节段性肾小球硬化中独特的金属蛋白酶排泄模式。
Pediatr Nephrol. 2011 Dec;26(12):2179-84. doi: 10.1007/s00467-011-1897-7. Epub 2011 Jul 1.
9
Matrix metalloprotease-9 induces transforming growth factor-β(1) production in airway epithelium via activation of epidermal growth factor receptors.基质金属蛋白酶-9 通过激活表皮生长因子受体诱导气道上皮细胞产生转化生长因子-β(1)。
Life Sci. 2011 Aug 1;89(5-6):204-12. doi: 10.1016/j.lfs.2011.06.008. Epub 2011 Jun 22.
10
Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis.通过尿蛋白质组分析诊断肾移植患者亚临床和临床急性 T 细胞介导的排斥反应。
Proteomics Clin Appl. 2011 Jun;5(5-6):322-33. doi: 10.1002/prca.201000153. Epub 2011 Apr 29.
Zotero 插件